Latest Inoviq (ASX:IIQ) News

AI cardiology, cancer research and pharma expansion drove the biggest moves in healthcare stocks this week. Investors paid up for fresh funding and regulatory wins, while some raisings and weak trading updates kept pressure on others.

INOVIQ Limited’s CAR-exosome platform demonstrated potent tumour-killing activity in ovarian cancer cell lines, eliminating up to 90% of cancer cells within 48 hours and reinforcing its potential against hard-to-treat solid tumours.

Healthcare stocks split into two camps this week: names with fresh data or contracts found buyers, while capital raisings and trial shock sent others sharply lower. The biggest move came from Cynata’s return to trade, but steady progress in Alzheimer’s, oncology, diagnostics and aged care software also kept the sector busy.

INOVIQ Limited confirms no undisclosed price-sensitive information amid recent share price surge, attributing the move to external research spotlighting upcoming EXO-OC ovarian cancer test data.

Biotech price swings were led by Dimerix’s slide, while TrivarX and LTR Pharma surged on clinical and commercial progress. Capital raisings, FDA milestones and first sales kept healthcare investors busy, but several early jumps faded as traders locked in gains.

INOVIQ Limited is on track to complete its EXO-OC™ ovarian cancer screening study by mid-2026 and is accelerating its CAR-exosome therapy program, supported by a strong cash position of A$11.9 million.

Two capital raisings and one brutal reset set the tone, even as several companies posted clean growth or strong clinical updates. Radiopharmaceuticals kept delivering good news, but investors still punished supply-chain and cash needs fast.

INOVIQ Limited reported a $3.96 million net loss for H1 2026, driven by increased R&D spend, while securing $10.2 million to accelerate its exosome-based cancer diagnostics and therapeutics pipeline.

A handful of healthcare names did the heavy lifting this week, driven by FDA wins, guideline upgrades, and big shifts in sales and cashflow. The flip side: several clinical-stage stocks fell hard as investors stayed picky about near-term proof and funding.

INOVIQ Limited has completed a $10.2 million capital raise to accelerate development of its exosome-based ovarian cancer screening test and CAR-exosome therapeutics, alongside key leadership appointments and promising preclinical results.

INOVIQ Limited has reported compelling preclinical results for its CAR-NK-exosome therapy targeting triple-negative breast cancer, showing significant tumor reduction and perfect survival in treated mice.

INOVIQ Limited has raised $9.5 million to advance its pioneering ovarian cancer screening test and CAR-exosome therapeutic programs, backed by strong preclinical data and strategic partnerships.